Comparing treatments for ovarian clear cell carcinoma
Part of Cancer, Women’s health & pregnancy clinical trials.
This study compares different ways to treat ovarian clear cell carcinoma, a rare type of ovarian cancer. It is for women whose cancer has come back or not gone away after platinum chemotherapy, or those newly diagnosed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 18 and 75 years old.
- You must have ovarian clear cell carcinoma (a specific type of ovarian cancer) confirmed by biopsy.
- If your cancer has come back or not gone away with treatment, you must have already had at least one round of platinum-based chemotherapy.
- You should be able to take care of yourself and do most daily activities (ECOG score 0–2).
- Your doctor expects you to live at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
This trial tests a combination of three drugs—liposomal irinotecan (chemotherapy), sintilimab (immunotherapy), and anlotinib (targeted therapy)—for people with recurrent or persistent ovarian clear cell carcinoma who have already tried platinum-based chemotherapy. The goal is to see if this triple therapy can shrink tumors or slow cancer growth.
This trial tests a new drug (sacituzumab tirumotecan) with or without pembrolizumab for ovarian clear cell cancer that has returned or spread. It's for people who have already had chemotherapy and one type of immunotherapy.
This trial tests a combination of two drugs—dostarlimab (an immunotherapy) and LB-100 (a new drug targeting a protein called PP2A)—for people with clear cell ovarian cancer that has returned or is resistant to platinum chemotherapy. The goal is to see if this combination is safe and effective for this specific type of cancer.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This Phase 2 trial compares two different treatment strategies as the first chemotherapy after surgery for advanced epithelial ovarian, peritoneal, or fallopian-tube cancer. It may help doctors find a more effective or better-tolerated approach for people in your situation.
Hear when a new Ovarian Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.